DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Trelegy Ellipta" report has been added to ResearchAndMarkets.com's offering.
Trelegy Ellipta ([fluticasone furoate + vilanterol + umeclidinium bromide]; GlaxoSmithKline) is a fixed triple combination inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) therapy. The product contains the same ICS/LABA components as Breo ([fluticasone furoate + vilanterol]; GlaxoSmithKline/Innoviva), plus a LAMA component, umeclidinium bromide.
GlaxoSmithKline received approval for Trelegy Ellipta in chronic obstructive pulmonary disease in Q3 2017, and is currently evaluating the drug in asthma patients whose symptoms are inadequately controlled by ICS/LABA therapies.
List of Figures
Figure 1: Trelegy Ellipta for asthma - SWOT analysis
Figure 2: Drug assessment summary of Trelegy Ellipta in asthma
Figure 3: Drug assessment summary of Trelegy Ellipta in asthma
Figure 4: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Trelegy Ellipta drug profile
Table 2: Trelegy Ellipta Phase III trials in asthma
Table 3: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
For more information about this report visit https://www.researchandmarkets.com/research/rrpz48/glaxosmithklines?w=4
